Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
Top Page
PROCEPT BioRobotics
(NASDAQ:PRCT)
58Neutral
Positive Factors
Guidance
PRCT's fiscal year 2025 revenue guidance has been raised, reflecting a year-over-year growth of 44%.
Revenue Growth
PRCT delivered a strong update that included sales of $69.2M, which is a 55% increase from the previous year and exceeded the expected $65.4M.
Negative Factors
Stock Performance
Despite the solid beat and raise, PRCT shares were down 6%.
Tariffs
There is concern about a 150 basis points gross margin headwind due to tariffs, which could impact financial performance.
PROCEPT BioRobotics (PRCT) vs. S&P 500 (SPY)
Market Cap
$2.88B
Dividend YieldN/A
Average Volume (3M)1.10M
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue Growth59.36%
EPS Growth19.87%
CountryUS
Employees756
SectorHealthcare
Sector Strength69
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.70
Shares Outstanding54,818,700
10 Day Avg. Volume1,370,634
30 Day Avg. Volume1,100,420
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.19
Price to Cash Flow (P/CF)-24.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$87.25Price Target Upside66.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
PROCEPT BioRobotics Business Overview & Revenue Model
Company DescriptionPROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
How the Company Makes MoneyPROCEPT BioRobotics generates revenue primarily through the sale and leasing of its AquaBeam Robotic System to hospitals and healthcare providers. The company's revenue streams also include recurring revenues from the sale of disposable handpieces and service agreements necessary for the operation and maintenance of the AquaBeam system. Additionally, PROCEPT BioRobotics may engage in strategic partnerships with medical institutions and other healthcare entities to expand the reach of its products and drive adoption. These partnerships can often provide additional revenue opportunities through collaborative endeavors and shared technological advancements.
PROCEPT BioRobotics Financial Statement Overview
Summary
PROCEPT BioRobotics is experiencing strong revenue growth and maintains a solid equity position. However, profitability remains a challenge due to negative margins and cash flows. The balance sheet is stable with low leverage, but there is a need for improved operational efficiency to achieve positive returns.Income Statement
PROCEPT BioRobotics has demonstrated strong revenue growth over the years, with total revenue increasing from $6.2 million in 2019 to $224.5 million in 2024, indicating a robust expansion trajectory. However, the company faces challenges with profitability, as reflected in negative net and EBIT margins due to high operating costs relative to revenue. Despite growing gross profit, achieving positive net income remains a critical goal.72
Positive
Balance Sheet
The balance sheet shows a strong equity position with stockholders' equity growing to $402.2 million in 2024. The debt-to-equity ratio is low, suggesting a conservative use of leverage, while the equity ratio indicates that the company is primarily equity-financed. However, the consistent net losses impact the return on equity, which remains negative, posing a challenge to profitability.65
Positive
Cash Flow
The company has improved its cash position significantly, with a substantial increase in cash and short-term investments. Although operating cash flow remains negative, indicating ongoing operational challenges, the firm has effectively raised capital through financing activities to support its growth. The negative free cash flow highlights the need for continued financial management to achieve sustainability.68
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 224.50M | 136.19M | 75.01M | 34.47M | 7.72M | Gross Profit |
| 137.10M | 71.05M | 37.09M | 15.87M | -1.25M | EBIT |
| -96.61M | -109.17M | -80.72M | -54.16M | -47.80M | EBITDA |
| -82.00M | -98.09M | -77.65M | -51.06M | -45.05M | Net Income Common Stockholders |
| -91.41M | -105.90M | -93.58M | -62.38M | -58.26M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 333.73M | 257.22M | 221.86M | 304.32M | 100.13M | Total Assets |
| 534.02M | 404.72M | 309.33M | 337.02M | 125.97M | Total Debt |
| 80.25M | 79.20M | 77.32M | 54.10M | 54.76M | Net Debt |
| -253.47M | -178.02M | -144.54M | -250.22M | -45.37M | Total Liabilities |
| 131.80M | 123.97M | 112.26M | 69.93M | 308.87M | Stockholders Equity |
| 402.22M | 280.75M | 197.07M | 267.09M | -182.89M |
| Cash Flow | Free Cash Flow | |||
| -103.62M | -133.21M | -83.03M | -57.93M | -48.58M | Operating Cash Flow |
| -99.21M | -108.00M | -80.38M | -57.33M | -48.34M | Investing Cash Flow |
| -4.41M | -25.21M | -2.65M | -592.00K | -233.00K | Financing Cash Flow |
| 180.13M | 167.79M | 3.61M | 262.12M | 106.77M |
PROCEPT BioRobotics Technical Analysis
Negative
52.49
Price Trends
58.69
Negative
69.98
Negative
73.43
Negative
Market Momentum
-1.77
Negative
43.19
Neutral
51.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRCT, the sentiment is Negative. The current price of 52.49 is below the 20-day moving average (MA) of 53.79, below the 50-day MA of 58.69, and below the 200-day MA of 73.43, indicating a bearish trend. The MACD of -1.77 indicates Negative momentum. The RSI at 43.19 is Neutral, neither overbought nor oversold. The STOCH value of 51.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRCT.
PROCEPT BioRobotics Risk Analysis
PROCEPT BioRobotics disclosed 76 risk factors in its most recent earnings report. PROCEPT BioRobotics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PROCEPT BioRobotics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $4.31B | 58.55 | 4.98% | ― | 7.41% | -22.10% | |
70 Outperform | $1.59B | 27.23 | 18.76% | ― | 26.08% | 30.54% | |
58 Neutral | $2.88B | ― | -27.62% | ― | 59.36% | 19.87% | |
54 Neutral | $2.03B | 32.45 | 4.87% | ― | 8.33% | 256.54% | |
51 Neutral | $5.32B | 3.41 | -40.36% | 2.89% | 17.93% | 2.52% | |
51 Neutral | $727.24M | ― | -9.99% | ― | 17.81% | 54.69% | |
51 Neutral | $70.92M | ― | -34.88% | ― | 28.44% | -61600.00% |
* Healthcare Sector Average
Performance Comparison
PRCT
PROCEPT BioRobotics
52.49
0.44
0.85%
ITGR
Integer Holdings
123.41
8.84
7.72%
UFPT
Ufp Technologies
206.80
-15.79
-7.09%
AXGN
AxoGen
16.40
9.74
146.25%
LIVN
LivaNova
37.26
-18.91
-33.67%
XTNT
Xtant Medical Holdings
0.51
-0.42
-45.16%
PROCEPT BioRobotics Earnings Call Summary
Earnings Call Date:Apr 24, 2025
(Q1-2025)
| % Change Since: -5.76%|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment Neutral
The earnings call demonstrated strong revenue growth and strategic advancements, particularly in system sales and Medicare coverage, but was tempered by significant net losses and potential tariff impacts.Q1-2025 Updates
Positive Updates
Strong Revenue Growth
Total revenue for the first quarter of 2025 was $69.2 million, representing growth of 55% compared to the first quarter of 2024.
US System and International Revenue Performance
US revenue for the first quarter was $60.3 million, representing a 50% growth, and international revenue was $8.9 million, showing a 104% increase compared to the prior year.
Significant Increase in Handpiece Sales
11,235 handpieces were sold in the US, representing a 65% year-over-year unit growth.
Favorable Clinical Outcomes
The WATER III trial showed aquablation therapy had a 0% transfusion rate and lower rates of ejaculatory dysfunction and incontinence compared to laser enucleation.
Positive Changes in Medicare Coverage
First Coast and Novitas, two large Medicare contractors, updated LCDs to streamline access to aquablation therapy for a broader patient population.
Growing Installed Base and Strategic Partnerships
The US installed base grew to 547 systems, with 43 systems sold in Q1, and 45% of the sales associated with IDN bulk buys.
Negative Updates
Net Loss and Operating Expenses
Net loss for Q1 2025 was $24.7 million, with total operating expenses of $71.6 million, up from $52.7 million in the prior year.
Potential Tariff Impact
Tariffs on imports from China could lead to a $5 million gross margin headwind, reducing guidance by 150 basis points if rates remain elevated.
Saline Shortage Impact
Residual impact from a saline shortage affected procedure volumes in January, though normalized in February and March.
Company Guidance
During the first quarter of 2025, PROCEPT BioRobotics Corporation reported a total revenue of $69.2 million, reflecting a 55% increase compared to the first quarter of 2024. The US revenue contributed $60.3 million, showing a 50% growth year-over-year. The company sold 43 robotic systems, priced at an average of $435,000, resulting in a US installed base of 547 systems, marking a 55% growth from the previous year. Additionally, handpiece sales in the US reached 11,235 units, with a year-over-year growth of 65%, generating $38 million in revenue. The gross margin for the quarter was 63.9%, up 750 basis points from the prior year. The company maintained a net loss of $24.7 million and adjusted EBITDA loss of $15.8 million. Looking forward, PROCEPT BioRobotics anticipates full-year 2025 revenue to be approximately $323 million, with the expectation of selling around 210 new robotic systems in the US. The guidance also includes a forecast for US handpiece sales to reach approximately 52,500 units, representing a 63% increase in unit volume compared to 2024.PROCEPT BioRobotics Corporate Events
Business Operations and StrategyFinancial Disclosures
PROCEPT BioRobotics to Present at Investor Conferences
Positive
Apr 25, 2025
PROCEPT BioRobotics announced its intention to present at investor conferences starting April 25, 2025, highlighting its recent achievements and future plans. The company has made significant strides, including FDA approvals, increased revenue, and expanded market penetration, positioning itself as a leading player in the BPH treatment market.
Spark’s Take on PRCT Stock
According to Spark, TipRanks’ AI Analyst, PRCT is a Neutral.
PROCEPT BioRobotics’ overall stock score reflects strong revenue growth and strategic progress. However, challenges such as negative profitability, bearish technical indicators, and valuation concerns weigh on the score. The company’s potential for future growth remains significant, but operational and financial improvements are necessary for a more positive outlook.
To see Spark’s full report on PRCT stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.